Navigation Links
Edison Pharmaceuticals, Inc. signs licensing agreement with Dainippon Sumitomo Pharma Co., Ltd. for development & commercialization of orphan mitochondrial and adult central nervous system disease drugs
Date:3/28/2013

ty of adult diseases.

The positive clinical results of a phase 2A trial of EPI-743 in children with Leigh syndrome were recently reported in Molecular Genetics and Metabolism (EPI-743 reverses the progression of the pediatric mitochondrial disease—Genetically defined Leigh Syndrome 107 (2012) 383-388). Separate manuscripts detailing EPI-743 treatment effect on CNS and systemic glutathione biomarker levels are also reported in Molecular Genetics and Metabolism (Brain uptake of Tc99m-HMPAO correlates with clinical response to the novel redox modulating agent EPI-743 in patients with mitochondrial disease 107 (2012) 690-699; Glutathione: A redox signature in monitoring EPI-743 therapy in children with mitochondrial encephalomyopathies (2013), in press). 

Edison Pharmaceuticals
Edison Pharmaceuticals is a specialty pharmaceutical company dedicated to developing treatments for children and adults with orphan mitochondrial diseases. EPI-743 is in phase 2 clinical development for the treatment of inherited respiratory chain disorders. Double-blind placebo-controlled trials are ongoing for the following indications: Leigh syndrome, Friedreich's ataxia, Cobalamin C defect, and Undiagnosed Disorders of Oxidation-Reduction. 

Dainippon Sumitomo Pharma Co., Ltd.
Dainippon Sumitomo Pharma Co., Ltd. (DSP) is a multi-billion dollar, top-ten listed pharmaceutical company in Japan with a diverse portfolio of pharmaceutical products. DSP aims to produce innovative pharmaceutical products in the psychiatry and neurology, which is designated as a key therapeutic area, as well as oncology. DSP has more than 7,000 employees worldwide. Additional information about DSP is available through its corporate website at www.ds-pharma.com.


'/>"/>
SOURCE Edison Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Edison Pharmaceuticals & Bambino Gesu Childrens Hospital Announce Initiation of EPI-743 Phase 2 Cobalamin C Deficiency Syndrome Clinical Trial
2. Samsung Medison Showcases New Medical Equipment and Technology with Samsung Electronics at RSNA 2012
3. Edison Pharmaceuticals Closes $20M Series F Financing
4. Edison Pharmaceuticals Announces Initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
5. Massive Hiring Event for Life Science Professionals in Edison, NJ on 9/18/12
6. Edison Pharmaceuticals Announces Positive Results of EPI-743 Phase 2A Leigh Syndrome Clinical Trial
7. EMA Grants Orphan Designation to Edison Pharmaceuticals for EPI-743 for Treatment of Leigh Syndrome
8. Carolinas HealthCare System and Edison Nation Collaborate to Drive Medical Innovation and Technology
9. Diabecline Antibiotic Receives Edison Award for Best New Pharmaceutical Product
10. Harwood Feffer LLP Announces Investigation of Spectrum Pharmaceuticals, Inc.
11. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Spectrum Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... March 31, 2015 /CNW/ - T-Bird Pharma Inc. (TSXV:TPI) ("T-Bird" ... premium quality medical marijuana products and a licensed producer ... Purposes Regulations ( Canada ) ("MMPR"), is ... The Corporation of the District of Saanich ... Company,s premises which now allows for commercial distribution of ...
(Date:3/31/2015)... -- Immune Pharmaceuticals Inc. ("Immune", the "Company") (NASDAQ: ... its planned bullous pemphigoid (BP) clinical development for bertilimumab, ... is an orphan auto-immune blistering disease of the skin ... Europe . As previously announced, ... II clinical trial in Israel ...
(Date:3/31/2015)... , March 31, 2015 ANI Pharmaceuticals, Inc. ... of Propafenone Hydrochloride 150mg, 225mg and 300mg oral tablets, ... The overall US market for Propafenone Hydrochloride 150mg, 225mg ... IMS Health. Arthur S. Przybyl , ... to announce the launch of our fourth product from ...
Breaking Medicine Technology:T-Bird Pharma Inc. Announces Final Municipal Rezoning Approval 2T-Bird Pharma Inc. Announces Final Municipal Rezoning Approval 3Immune Pharmaceuticals To Expand Bullous Pemphigoid Clinical Development Plan For Bertilimumab 2Immune Pharmaceuticals To Expand Bullous Pemphigoid Clinical Development Plan For Bertilimumab 3Immune Pharmaceuticals To Expand Bullous Pemphigoid Clinical Development Plan For Bertilimumab 4ANI Pharmaceuticals Announces the Launch of Propafenone Tablets 2ANI Pharmaceuticals Announces the Launch of Propafenone Tablets 3
... ROYAL OAK, Mich., March 4, 2011 Doctors ... minimally invasive robotic procedure to correct atrial fibrillation, ... new robotic maze procedure is an alternative to ... with fewer complications and a shorter hospital stay. ...
... March 4, 2011 The pressure for a new ... with organizations across the pharmaceutical sector facing pipeline deficits, ... Facing an ever-changing launch landscape, product launch leaders are ... therapies through the labyrinth of regulatory and marketplace challenges. ...
Cached Medicine Technology:Beaumont First in State to Perform Robotic Heart Procedure for Atrial Fibrillation 2Beaumont First in State to Perform Robotic Heart Procedure for Atrial Fibrillation 3Pharmaceutical Launch Excellence Services Delivers Market Entry Road Map 2
(Date:3/31/2015)... 2015 When SIGVARIS launched the EVERSHEER compression ... product launch to date. Women immediately fell in love with ... another reason to love EVERSHEER with the launch of a ... , Lavender mist pairs perfectly with a variety of navy, ... women looking to add a hint of spring to their ...
(Date:3/31/2015)... The report “Coagulation/Hemostasis Analyzer Market By product ... Prothrombin Time/INR, D-Dimer, Fibrinogen), Technology (Mechanical, Optical), End ... studies the major market drivers, restraints, opportunities and ... Rest of the world (RoW). , The ... $3.58 billion by 2019 from $2.4 billion in ...
(Date:3/31/2015)... Safeware has been recognized ... Central Ohio, an awards program presented by Columbus Business ... the awards program, held on March 10, 2015. These ... health, with outstanding health and wellness initiatives. , ... a healthy environment for their associates. Business Frist, OhioHealth ...
(Date:3/31/2015)... Spring Hill, FL (PRWEB) March 31, 2015 ... and Substance Abuse (CASA) at Columbia University states that ... arrested in the U.S. and enter state juvenile justice ... abuse problems, are under the influence of drugs or ... of these factors. Despite this high incidence of substance-related ...
(Date:3/31/2015)... A' Design Award and Competition is pleased ... Daniel Dion has been announced as a winner of ... Devices and Research Equipment Design Competition Category. ... behind the award winning Medical Product design Bruker EVOQ ... direction of Dr. Rohan Thakur and the Bruker team ...
Breaking Medicine News(10 mins):Health News:Put Spring in Your Step with SIGVARIS’ Top Selling Sheer Hosiery Compression Therapy Brand 2Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 2Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 3Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 4Health News:Safeware Recognized as a Healthiest Employer in Central Ohio 2Health News:$14.4 Billion Annual Price Tag: Suncoast Rehab Center Questions Harsh Sentencing of Juvenile Drug and Alcohol Offenders 2Health News:$14.4 Billion Annual Price Tag: Suncoast Rehab Center Questions Harsh Sentencing of Juvenile Drug and Alcohol Offenders 3Health News:$14.4 Billion Annual Price Tag: Suncoast Rehab Center Questions Harsh Sentencing of Juvenile Drug and Alcohol Offenders 4Health News:Daniel Dion wins Golden in A' Medical Product Design Awards 2
... Osteotech, Inc.,(Nasdaq: OSTE ) announced today that third ... third quarter 2006 revenue of $23.4,million. Revenue from Osteotech,s ... for the three months ended September 30,2007 as compared ... for the,third quarter of 2006. Gross margin improved to ...
... 6 /PRNewswire-FirstCall/ - Bioniche Life Sciences,Inc. (TSX: BNC), ... Cameron Groome, Executive,Vice-President, Corporate & Strategic Development, will ... Healthcare Conference in New York City,tomorrow. Mr. Groome ... the Holmes,II Room of the New York Palace ...
... by web cast-, TORONTO, Nov. 6 /PRNewswire-FirstCall/ ... in the research,development and commercialization of pharmaceutical products ... that on,Wednesday, November 7, 2007, at 10:30 a.m. ... and CEO will present a corporate overview of ...
... Elite Books, TUCSON, Ariz., Nov. 5 We all ... the development of Alzheimer,s Disease and heart,disease, along with a ... In her seminal book, The Apo E Gene Diet: ... Body,s Own Genes,(Elite, Hardcover, $27.95, November 1, 2007), Pamela McDonald, ...
... 5 StatSure Diagnostic,Systems, Inc. (OTC Bulletin Board: ... Administration ("FDA"), through its Center for Devices and,Radiological ... Laboratory,Improvements Amendments of 1988 ("CLIA") for an HIV ... The HIV 1/2 product,is marketed and distributed worldwide ...
... offices could ... YORK, Nov. 5 Group Health Incorporated (GHI) and,HIP ... educational seminar in,New York City on November 6 for ... be held at HIP,headquarters, 55 Water St., will provide ...
Cached Medicine News:Health News:Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09 2Health News:Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09 3Health News:Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09 4Health News:Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09 5Health News:Bioniche to Present at Rodman & Renshaw 9th Annual Healthcare Conference 2Health News:Lorus announces presentation of corporate overview at the Rodman and Renshaw Annual Healthcare Conference 2Health News:Groundbreaking Apo E Gene Diet Linked to Alzheimer's Disease and Heart Disease Prevention 2Health News:StatSure's Patented HIV 'Barrel' Technology Receives CLIA Waiver From FDA 2Health News:StatSure's Patented HIV 'Barrel' Technology Receives CLIA Waiver From FDA 3Health News:GHI and HIP Lead Effort to Expand Electronic Health Record System Throughout the City of New York 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: